Ranbaxy Laboratories Ltd., of Mumbai, India, said European regulators finalized assessment of reports of noncompliance with GMP at the firm's manufacturing site in Toansa, India, which led to the suspension of the GMP certificate in the European Union in January, and said, while there were a number of deficiencies at the concerned site, assessment of all available information reassured regulators that there has been no risk to public health.